The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 15, 2016

Filed:

Mar. 22, 2011
Applicants:

Darby Schmidt, Arlington, MA (US);

Subharekha Raghavan, Teaneck, NJ (US);

John Stelmach, Westfield, NJ (US);

Jian Guo, Scotch Plains, NJ (US);

Jonathan Groeper, Metuchen, NJ (US);

Linda Brockunier, Orange, NJ (US);

Keith Rosauer, Laurence Harbor, NJ (US);

Hong Shen, West Windsor, NJ (US);

Rui Liang, East Brunswick, NJ (US);

Fa-xiang Ding, Staten Island, NY (US);

Inventors:

Darby Schmidt, Arlington, MA (US);

Subharekha Raghavan, Teaneck, NJ (US);

John Stelmach, Westfield, NJ (US);

Jian Guo, Scotch Plains, NJ (US);

Jonathan Groeper, Metuchen, NJ (US);

Linda Brockunier, Orange, NJ (US);

Keith Rosauer, Laurence Harbor, NJ (US);

Hong Shen, West Windsor, NJ (US);

Rui Liang, East Brunswick, NJ (US);

Fa-Xiang Ding, Staten Island, NY (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 403/14 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 403/14 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.


Find Patent Forward Citations

Loading…